REG - Retroscreen Vlgy Grp - New Ordinary Shares <Origin Href="QuoteRef">RVG.L</Origin>

hVIVOAnnouncement

04/03/2015 07:01

RNS Number : 4572G
Retroscreen Virology Group PLC
04 March 2015
For immediate release 07.00: 4 March 2015
RETROSCREEN VIROLOGY GROUP PLC
("Retroscreen" or the "Company")
ISSUE OF ORDINARY SHARES
The Company has issued 438,072 ordinary shares of 5p each ("Ordinary Shares" or the "Issue"), in relation to deferred consideration for the acquisition of Activiomics Limited (233,187 ordinary shares) and an exercise of warrants by Numis Securities Limited (204,885 ordinary shares). Following the Issue, there are no shares outstanding relating to the deferred consideration of Activiomics Limited and no warrants outstanding exercisable by Numis Securities Limited. 
Application has been made for the Ordinary Shares to be admitted to AIM, with trading expected to commence on 9 March 2015 ("Admission"). Upon Admission, the shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.
As a result of the Issue, the total number of ordinary shares in issue is 68,097,515, which is the number which may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interests in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
For further information please contact:
Retroscreen Virology Group plc+44 207 756 1300
Kym Denny (CEO)
Graham Yeatman (FD) 
Media Enquiries +44 203 021 3933 / +44 7854 979 420
Colin Paterson (Director of Marketing, Communication and Public Relations)
Numis Securities Limited  +44 207 260 1000 
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
Retroscreen Virology Group plc ("Retroscreen") is a rapidly growing life sciences company based in the UK pioneering a technology platform called hVIVO which uses human models of disease involving healthy volunteers to discover and study new drugs and diagnostics. To date, Retroscreen has conducted over 35 clinical studies, involving more than 1800 volunteers for a range of leading industry, governmental and academic clients.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
IOEEAPDDESNSEFF